(0.69%) 5 081.25 points
(0.44%) 38 237 points
(0.91%) 17 598 points
(0.56%) $79.44
(1.97%) $1.970
(-0.10%) $2 308.70
(-0.85%) $26.52
(0.42%) $958.90
(0.15%) $0.934
(0.42%) $11.08
(0.09%) $0.799
(-1.57%) $91.80
Live Chart Being Loaded With Signals
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions...
Stats | |
---|---|
本日の出来高 | 1.62M |
平均出来高 | 4.22M |
時価総額 | 5.38B |
EPS | €0 ( 2024-02-28 ) |
次の収益日 | ( €0 ) 2024-05-14 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 98.84 |
ATR14 | €0.00600 (0.07%) |
ボリューム 相関
Grifols, S.A. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Grifols, S.A. 相関 - 通貨/商品
Grifols, S.A. 財務諸表
Annual | 2023 |
収益: | €6.59B |
総利益: | €2.32B (35.24 %) |
EPS: | €0.0873 |
FY | 2023 |
収益: | €6.59B |
総利益: | €2.32B (35.24 %) |
EPS: | €0.0873 |
FY | 2022 |
収益: | €6.06B |
総利益: | €2.23B (36.80 %) |
EPS: | €0.310 |
FY | 2021 |
収益: | €4.93B |
総利益: | €1.96B (39.78 %) |
EPS: | €0.267 |
Financial Reports:
No articles found.
Grifols, S.A.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。